Boston Scientific acquires Valencia Technologies and Penumbra in deals totaling $14.5B — DBS company bets on neural access expansion
Summary
Boston Scientific announced agreements to acquire Valencia Technologies Corporation and Penumbra Inc. in deals totaling approximately $14.5 billion in early 2026, as noted in Neurotech Notables #46. Valencia Technologies develops eCoin — an implantable peripheral nerve stimulator for overactive bladder targeting the tibial nerve — representing Boston Scientific's expansion into a new peripheral neuromodulation indication. Penumbra develops neurovascular intervention systems for stroke thrombectomy, hemorrhagic stroke, and peripheral vascular conditions. The combined acquisitions position Boston Scientific as the broadest portfolio neuromodulation company in the world, spanning DBS (via their existing Vercise platform), spinal cord stimulation, peripheral nerve, and now neurovascular intervention.
Why it matters
Boston Scientific spending $14.5B on neuromodulation expansion in a single announcement is the largest capital commitment to the neurostimulation sector in history. The combination of Valencia (peripheral nerve for bladder) and Penumbra (neurovascular intervention for stroke) signals BSci's thesis that the future of neurology is device-mediated across multiple neural pathways — not limited to the brain and spine where they already compete with Medtronic and Abbott.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial